Super Disintegrants Research Articles

Formulation and Evaluation of Rosuvastatin Calcium Immediate Release Tablets Using Beta Cyclodextrin

In order to treat Hyperlipidaemia, Rosuvastatin, a Dyslipidaemia drug, inhibits the HMG-CoA reductase enzyme. However, the calcium form of Rosuvastatin (RST) has low bioavailability, undesirable dissolving characteristics, and issues with absorption. Thus objective of the study is to increase the solubility and dissolution rate of Rosuvastatin calcium a poorly water-soluble 3-hydroxy 3-methyl glutaryl CoA (HMG-CoA) Reductase inhibitor through inclusion Complexation with β-cyclodextrin (β-CD). Therefore, the goal of the current study was to create a Rosuvastatin tablet formulation for oral dissolution. Rosuvastatin immediate tablets were developed using the direct compression showed good results, the prepared inclusion complex with β-CD by kneading method exhibited greatest enhancement in solubility and fastest dissolution (97.363) % RST release in 15 min. The inclusion complex contains RST: β-CD (1:1) and (1:2) was formulated into tablets using super disintegrants like Sodium starch glycolate, Cross povidone and Croscarmellose. All the mentioned batches were prepared and granules were evaluated for pre-compression parameters such as bulk density, tapped density and compressibility index. Tablets were evaluated for weight variation, thickness, hardness, friability; disintegration time and were found to be within the limits. In vitro dissolutions were carried out in 0.05M phosphate buffer with a pH of 6.8. The prepared tablet was evaluated for various post compression parameters like hardness, friability, weight variation, thickness, and in-vitro dissolution.

Anti-diabetic Effect of Sprouted Trigonella foenumgraecum L. Seed Solid Dosage Form in Low-dose Streptozotocin Induced Diabetic Rats

Abstract: Background: Trigonella foenum-graecum L (Fenugreek) is an annual herb, mainly cultivated for its seed as well as for its sprouts. Pharmacological investigations reported anti-bacterial, anti-diabetic, anti-cancer, anti-diarrheal, anti-hypercholesteremic, and antiinflammatory activities of Trigonella foenum-graecum L. Aim: The purpose of this study was to accentuate on formulation of granules and investigate the effect of germinated Trigonella foenum-graecum L. (TFG) granules in Diabetes mellitus (DM) rats induced by streptozotocin as fenugreek retains hypoglycemic property. Materials and Methods: Granules of germinated TFG powder were arranged by means of several excipients comprising diverse amounts of super disintegrants by (wet) granulation method and proceed for the solid dosage form evaluation. Further, in-vivo study was performed in STZ induced DM Wister rats for four weeks. TFG granules 1600mg/kg and Glibenclamide 0.45 mg/kg (as a positive control for comparison) were orally administrated and evaluate the diabetics in rats. Results: All evaluation parameters are correct: as in standard tablet. The STZ (Streptozotocin) induced rats the treatment with the Drug (Glibenclamide) and TFG granules significantly lowered the blood plasma glucose levels by 36% (mean ± SD glucose 120 ± 0.6 mg/dL (p < 0.001)) and 38% (mean ± SD glucose 114 ± 0.4 mg/dL; p < 0.001) respectively after 4 weeks of treatment when compared to T2DM (Type 2 Diabetes mellitus) rats. Conclusion: Experimental studies had shown that bioactive compounds found in Trigonella Foenum graceum herb have potential to cure diabetes especially due to the presence of unique chemical constituent including trigonelline, galactomannan and amino acid 4-hydroxy isoleucine. These findings suggested that TFG granules may be an alternative medicine for the management of DM. Keywords: Trigonella foenum-graecum, Fenugreek, Anti-diabetic, Tablet, Diabetes mellitus.

Formulation and Evaluation of Aripiprazole Oral Disintegrating Tablets

Aim: This work aims to develop oral disintegrating tablets from solid dispersion of aripiprazole that are capable of enhancing solubility.&#x0D; Methodology: Aripiprazole an antipsychotic is a BCS class IV drug with Oral bioavailability of 87%. To enhance the solubility of this drug the solid dispersions were prepared by using a combination of β-Cyclodextrin and PVP K30 in 1:1, 1:2 by using a physical mixture and solvent evaporation method. The prepared solid dispersions were analyzed for all the physical parameters and drug excipient interactions. The solid dispersion was optimized for the preparation of oral disintegrating tablets by direct compression technique using different concentrations of various natural super disintegrants namely Tapioca starch, Amorphophallus campanulactus, and synthetic super disintegrants namely Sodium starch glycolate, crospovidone.&#x0D; Results: FTIR showed that the drug and excipients are compatible with each other. Among all the solid dispersion formulations SCD6 (Drug: β-cyclodextrin) shows a high percentage of drug release i.e., 98.58±0.28% for 45 min, and solubility was found to be 0.954±0.32mg/ml. Percentage practical yield was found to be 98.36±0.14% and drug content was found to be 97.31±0.04%. SCD6 formulation was optimized for the preparation of oral disintegrating tablets. The post-compression parameters of all the prepared tablets were within the limits. Among all, F3 formulations containing tapioca starch, 7.5% were found to possess a better disintegration time (28±1.52sec) and in-vitro dissolution (98.64±0.29% for 45min).&#x0D; Conclusion: It can be concluded that solid dispersions of Aripiprazole incorporated in oral disintegrating tablets are a very useful approach for better release of Aripiprazole in an efficient manner.

Formulation and Evaluation of Time-Controlled Pulsatile Release Rosuvastatin Press-Coated Tablets

Rosuvastatin belongs to the HMG-CoA reductase inhibitor class of drugs (statins). The main aim of the present study was to formulate and evaluate time-controlled pulsatile release Rosuvastatin press-coated tablets. The core tablets were formulated by the Direct compression method. Coated tablets were formulated by the Press-coating technique. The drug delivery system was designed to deliver the drug at a specific time for the patient suffering from Hyperlipidemia. The core tablets containing Rosuvastatin, anhydrous lactose, and different ratios of super disintegrants like croscarmellose sodium, and sodium starch glycolate, among six core tablets were formulated, and they were evaluated for post-compression parameters like Weight variation, Thickness, Hardness, Friability, Disintegration, and In-vitro drug release profile, then the core was optimized by using different ratios of polymers such as Eudragit-S100, Eudragit-L100, and HPMC K4M, Ethyl Cellulose (1:2, 2:1 ratios). Totally four coating compositions were fixed and coated to core tablets by press-coating method, then they were evaluated for post-compression parameters like Weight variation, Hardness, Thickness, and In-vitro drug release studies were performed in 0.1 N HCl for 2 hrs, pH 6.8 phosphate buffer for 6 hrs and pH 7.4 phosphate buffer from the dissolution data the coat containing Eudragit-S100, Eudragit-L100 (2:1) combination shown best profile for pulsatile release of Rosuvastatin. The 10 hrs of lag time for the drug release and the drug release were depending on the effects of the composition of the polymers used.

Formulation and the Study of Finished Products used for Anginal Disease

Congestive heart failure is a type of disease which is mainly observed due to the improper supply of blood to the heart. In this disease patient feels severe pain in the chest and may cause serious illness. Sudden treatment is needed in this disease to prevent any fatality. Nitroglycerin is the choice of drug for this disease. This study prepares a dosage form that can deliver the drug at a fast rate like a sublingual tablet of nitroglycerin. Sublingual dosage form was manufactured by direct compression method. For the formulation, multiple excipients like super disintegrants, sweeteners and lubricants were used. The finished dosage form was evaluated for different quality parameters. Optimum formulation was compared with the marketed product and kept on the accelerated stability study. Results were observed as satisfactory and comparable with the marketed product.

Development and Evaluation of Kukkutandatvak bhasma tablet by using Dry Granulation Techniques

Aims: This study aimed to formulate and evaluate Kukkutandatvak (Hen Eggshell) bhasma tablet intended for optimum disintegration and release in the gastrointestinal tract. Methods and Material: Calcium content in Kukkutandatvak bhasma was determined using the titrimetric method. 9 formulations (F1 to F9) were prepared with Polyvinylpyrrolidone and SGS as super disintegrants. The granules were then evaluated for angle of repose, bulk density, tapped density, Hausner's ratio and Carr's index. The granules were then converted into caplet shaped tablets and were evaluated for uniformity of weight, drug content, friability, Hardness, Disintegration (in a sec) and % drug release. Results and Discussions: Calcium content in Kukkutandatvak bhasma was found to be 98%. The granules were found to be free-flowing and compressible. The Kukkutandatvak bhasma tablet had good strength and lower disintegration time (less than 135 sec), indicating a better balance between the binding and disintegration properties. The antacid activity of the tablet was evaluated by preliminary antacid test, i.e. acid-neutralizing capacity test and Rosset-Rice test. Conclusions: It was observed that Kukkutandatvak bhasma tablet (500 mg) prepared by both methods comply with Preliminary Antacid Test U.S.P. The tablet prepared neutralized 15.15 mEq of respectively in just 9.25min.

Central Composite Designed Fast Dissolving Tablets for Improved Solubility of the Loaded Drug Ondansetron Hydrochloride.

Ondansetron tablets that are directly compressed using crospovidone and croscarmellose as a synthetic super disintegrant are the subject of this investigation. A central composite, response surface, randomly quadratic, nonblock (version 13.0.9.0) 32 factorial design is used to optimize the formulation (two-factor three-level). To make things even more complicated, nine different formulation batches (designated as F1–F9) were created. There were three levels of crospovidone and croscarmellose (+1, 0, -1). In addition to that, pre- and postcompressional parameters were evaluated, and all evaluated parameters were found to be within acceptable range. Among all postcompressional parameter dispersion and disintegration time, in vitro drug release experiments (to quantify the amount of medication released from the tablet) and their percentage prediction error were shown to have a significant influence on three dependent variables. Various pre- and postcompression characteristics of each active component were tested in vitro. Bulk density, tap density, angle of repose, Carr's index, and the Hausner ratio were all included in this analysis, as were many others. This tablet's hardness and friability were also assessed along with its dimension and weight variations. Additional stability studies may be conducted using the best batch of the product. For this study, we utilised the Design-Expert software to select the formulation F6, which had dispersion times of 17.67 ± 0.03 seconds, disintegration times of 120.12 ± 0.55 seconds, and percentage drug release measurements of 99.25 ± 0.36 within 30 minutes. Predicted values and experimental data had a strong correlation. Fast dissolving pills of ondansetron hydrochloride may be created by compressing the tablets directly.

Development and characterization of hydralazine mouth dissolving tablet

Tablet dosage form is the most popular among all existing conventional dosage forms because of its convenience of self-administration, compactness and easy manufacturing. Many patients find it difficult to swallow tablets and capsules. The difficulty is experienced in particular by pediatric and geriatric patients, but it also applies to people who are ill on bed and to those active working patients who are busy or traveling, especially those who have no access to water. The drug hydralazine HCl were used. The amount of drug was 35 mg. the different super disintegrates was used to make a suitable mouth dissolving tablet. All the other reagents which is used in analytical grade reagents. In the present study mouth dissolving tablets of hydralazine HCl were designed, prepared and evaluated. These tablets can disintegrate or dissolve rapidly once placed into the oral cavity. The feofenadine was analyzed for its organoleptic, physicochemical and spectral (IR, UV) properties. The obtained hydralazine HCl was concordant with reference specifications. A complex of hydralazine HCl was successfully formulated. The volunteers rated the resinate as tasteless and agreeable complex.

Formulation and in vitro evaluation of bilayer tablets of bicalutamide and koenimbine

This work is about developing, optimizing, and testing In vitro a bilayer tablet with Koenimbine (KNB) in the immediate release layer and bicalutamide (BCT) in the sustained release layer. Sodium starch glycolate is used as a super disintegrant in the immediate release layer, and the hydrophilic matrix HPMC-K100 is used in the sustained release layer. Bilayer tablet showed initial burst effect to provide dose of immediate release layer Koenimbine to control the acid secretion level and the sustained release of bicalutamide for 24 hours. The prepared bilayer tablet was tested for its precompression parameters, physical properties like hardness, friability, uniformity of weight, uniformity of drug content, swelling index, and In-vitro drug release. In 45 minutes, 100.37 ± 0.35 percent of the Koenimbine in the immediate release layer was found to be released. In 24 hours, 98.32% of the bicalutamide in the layer with slow release was found to have been released. Koenimbine makes bicalutamide work better. So, bilayer tablets of koenimbine and bicalutamide were used to get more patients to take their medicine so that prostate cancer could be treated better.

Formulation and in-vitro Evaluation of Oro-dispersible tablets of Indomethacin

Introduction: Oro-dispersible tablets are rapidly dissolved in saliva without the need for water and are beneficial for renal impaired, bedridden and psychiatric patients. Objective: The study aimed to formulate oro-dispersible tablets of indomethacin with reduced adverse effects, better patient compliance, faster action, and convenience for patients. Methods: Oro-dispersible tablets of indomethacin were prepared using three different super disintegrants; crospovidone, croscarmellose sodium and sodium starch glycolate with three different concentrations (2.5%, 5.2%, and 7.7%) by direct compression method. The prepared tablets were evaluated for pre and post-compression parameters including bulk density, tapped density, compressibility index, angle of repose, Hausner's ratio, hardness, friability, wetting time, in vitro disintegration time, and in vitro drug release. Results: The percentage of drug released in 5 minutes of all formulations of Oro-dispersible tablets of Indomethacin was found to be 74.36% to 80.16% and the percentage of drug released in 10 minutes was 96.18% to 100%. All formulations showed disintegration time in the range of 19-78 seconds. The tablets prepared with 7.7% crospovidone (F6) shows faster disintegration (19 seconds) as compared to tablets prepared with sodium starch glycolate and croscarmellose sodium. The in-vitro dissolution studies showed that tablets of formulations batch containing 7.7% crospovidone releases 100% of the drug after 10 minutes which was fast released as compared to sodium starch glycolate and croscarmellose sodium. Conclusions: Oro-dispersible tablets of indomethacin prepared with crospovidone showed better disintegration time and dissolution profile as compared to other superdisintegrants.

Formulation and evaluation of polyherbal anti-diabetic tablet for oral drug delivery system

The Present Investigation was aimed to develop a Polyherbal tablet formulation for effective treatment of diabetes mellitus. Polyherbal tablets containing various Herbal extracts were prepared using different super disintegrants in varying concentrations to achieve minimum disintegration time. Pre-compression Parameters for all blends were within acceptable range of pharmacopoeial specifications. Formulation F4 showed minimum disintegration time of 14.20 minutes. Hence, it was selected as an optimised formulation and subjected to stability study. Stability study results revealed that, formulation F4 was a stable formulation having better disintegration time and % friability and could be used for effective treatment of diabetes mellitus.

Study on the evaluation and formulation of zolpidem tartrate

Traditional solid dose forms have a number of drawbacks, including difficulties in swallowing as patients get older, a delayed commencement of action, and issues with physiological factors such as the length of time it takes for the stomach to empty. A tablet that dissolves in the mouth is a relatively recent development in the field of drug delivery. The use of zolpidem in the treatment of insomnia for a relatively short period of time is preferred. The purpose of this study is to improve the bioavailability of zolpidem tartrate and get around the effect of the first transit through the body by formulating and evaluating mouth-dissolving tablets of the drug. The tablet containing Zolpidem was made by employing the directed compression method, with croscarmellose sodium and sodium starch glycolate serving as the super disintegrants, and mannitol, microcrystalline cellulose, and dicalcium phosphate serving as the diluents. The effects of several super disintegrants and diluents on disintegration and dissolving time were optimized, and the formula was completed on the basis of these characteristics. The FTIR investigation revealed that the medication and the excipients were compatible with one another. According to the results of the pre-compression investigation, the bulk powder possesses outstanding flow qualities and falls within a range of pharmacopoeia standards that is considered acceptable. The findings of the post-compression evaluation of the parameters match the criterion that was anticipated. From all of the different formulations, the one that had the highest amounts of sodium starch glycolate (35 mg), mannitol (20 mg), and microcrystalline cellulose yielded the greatest results for the In vitro drug release profile (60 mg). These tablets have a hardness that is lower than 4 kg/cm2, a disintegration period that is only 24 seconds long, and they release 97.71 percent of their pharmacological content within 30 minutes.

SELECTION AND OPTIMIZATION OF MOST EFFICIENT SUPERDISINTEGRANT FOR THE FORMULATION OF DISPERSIBLE TABLETS OF TRAMADOL HYDROCHLORIDE

Objective: The intent and objective of this research work were to find out the most effective superdisintegrants on the basis of disintegration time dissolution rate and other secondary tablet properties among the three mostly used superdisintegrants (Crospovidone, sodium starch glycolate and croscarmellose). This endeavour was initiated to mitigate dysphagia and for better bioavailability of drugs. Methods: Nine formulations of Tramadol HCl (50 mg) dispersible tablets were fabricated by direct compression process using different concentrations (3%, 5% and 8%) of mentioned superdisintegrants. Dispersible tablets were formulated and evaluated for various parameters such as thickness, hardness, friability, weight variation, disintegration time, drug content and dissolution rate. Then the stability study was carried out on the selected formulation batch to get a conclusion. Results: Results were interpreted in mean±SD where the value of n is equal to 3. The formulated dispersible tablets were evaluated for their post-compression parameters after achieving the desired pre-compression attributes. In pre-compression evaluation, the flow property and compressibility of powder were checked and the results found to be acceptable of all the nine formulations having an angle of repose less than 19 °, compressibility index in the range of 14.45 to 15.27 and Hausner’s ratio (≤ 1.29). The thickness of the tablets was found to be 4.19 to 4.28 mm. The tablets have optimum hardness just above 4 kg/sq. cm for better sustainability against mechanical stress and the percentage loss on friability found to be less than 1%. The drug content in the tablets of all nine formulations was found to be in the range of 97.48±0.9% to 99.46±0.4%. The wetting time and disintegration time were found to be within 20 sec and 40 sec, respectively, for all nine batches. The dissolution profile showed that more than 97% of the drug were released within 14 min, which is a great achievement in comparison to marketed dispersible tablets. The formulation batch (B2) with crospovidone as superdisintegrant has shown supremacy in tableting properties with better disintegration and dissolution profile. The bioavailability of the drug would be enhanced due to the increment in these parameters. The results of the stability studies of formulation batch (B2) were satisfactory. This batch with crospovidone as a super disintegrant was selected as the best formulation and recommended for scale-up. Conclusion: The outcome of the research work suggests that the disintegration efficiency of crospovidone is the most among the three super disintegrants and is recommended for the formulation of most effective dispersible tablets of Tramadol Hydrochloride.

A recent solidification approach for nanosuspension: formulation, optimisation and evaluation of canagliflozin immediate release pellets.

Abstract.

Formulation and Evaluation of Nimodipine Tablets Using Solid Dispersion Technique

The present study is an attempt to develop immediate release tablets of Nimodipine using solid dispersion technique to achieve rapid release in GIT which might result in enhanced absorption and thereby improved bioavailability. Various batches of Nimodipine solid dispersion (SD1-SD6) were prepared using fusion method, solvent evaporation and combination of these two methods (melt evaporation method/melting solvent method). PEG 6000 and PVP K30 were used as polymeric carrier in (drug: carrier) 1:1 ratio for all the formulations. Docusate sodium was used as surfactant in 0.025% to 0.085%. Drug-excipients interactions were carried out for pure drug and optimized formulations using FTIR studies. Six batches of Nimodipine immediate release tablets (F1 to F6) were developed by wet granulation method using its solid dispersion. Crospovidone was selected as super disintegrant and acetone as an organic solvent. All the batches of immediate release tablets were evaluated for different pre-compression and post-compression parameters including stability study of the optimized formulation. Among all formulations, F6 prepared by melt evaporation method with a high surfactant content showed the greatest drug release (101.49% ± 0.31%). The stability studies (formulation F6) showed there was no major differences in physical parameters and was stable even after a period of 3 months. % CDR of the accelerated time stability batch was 94.41% ± 0.265% of its content in 30 min which is showing immediate release and the drug content of the same stability batch was 99.87% ± 0.119%.

Formulation and evaluation of serratiopeptidase and salbutamol tablet for dysphagia

Oral Dispersible Tablet of Serratiopeptidase and salbutamol were prepared, evaluated and different types of concentration and dissolution of tablets were studied. In FTIR, drug and excipients with their mixture showed that there is no interaction between the drug molecule and excipients used. The Percentage of drug content of tablets in the formulations was found to be 95 % to 105% which complies with the limits of pharmacopoeia. By the process of direct compression method was used to prepare oral Dispersible tablet containing 300 mg of Serratiopeptidase and salbutamol. formulation was conducted using different concentrations of croscarmellose, micro crystalline cellulose, as a super disintegrants. And their interaction with Serratiopeptidase and salbutamol also evaluated using FTIR.

A REVIEW ON FAST DISSOLVING TABLET

Fast dissolving tablets (FDTs) emerged as one of the popular and widely accepted dosage forms. Few solid dosage forms like capsules and tablets are present days facing the problems like difficulty in swallowing (dysphagia) resulting many incidences of non-compliance and making the therapy ineffective. Specifically for paediatric patients because of incomplete development of the muscular and nervous system and case of geriatric patients suffering from Parkinson’s disorder. Oral dosage form and oral route are the most preferred administration route for various drugs with limitations like first-pass metabolism, bedridden, psychiatric patients and uncooperative patients. There is no need of excess water to dissolve and disintegrate FDT tablets. Fast dissolving tablets are designed to dissolve in within 60 seconds in saliva remarkably faster. FDTs formulations contain super disintegrants to enhance the disintegration rate of tablet in the buccal cavity. FDTs have disintegrated quickly, absorb faster so, in vitro drug release time improve and this property of drugs (dosage form) enhanced bioavailability. FDTs have advantages such as easy portability and manufacturing, accurate dosing, good chemical and physical stability and an ideal alternative for geriatric and paediatric patients. FDT formulations have advantage over both conventional tablets and liquid dosage form.

Formulation and Evaluation of Buccal Disintegrating Tablet of Anticonvulsant Drug

Oral and Buccal delivery is currently the gold standard in the pharmaceutical industry where it is regarded as the safest, most convenient and most economical method of drug delivery having the highest patient compliance. To troubleshoot such problems a new dosage form known as Buccal and orally disintegrating tablet, has been developed which rapidly disintegrate and dissolve in saliva and then easily swallowed without need of water which is a major benefit over than conventional dosage form. In addition, patients suffering from dysphasia, motion sickness, repeated emesis and mental disorders prefer such preparation because they cannot swallow large quantity of water. the immediate release of medication and for instant release at desire location in which the drug is absorbed distributer and easily metabolized. e.g. To prepare and characterize buccal tablets of Gabapentin using different super disintegrants such as Cross povidon, PVP K30, Micro crystalline cellulose. This types of formulation of improving solubility of drug and development of Buccal drug delivery system.

Formulation of Ebastine Fast-Disintegrating Tablet Using Coprocessed Superdisintegrants and Evaluation of Quality Control Parameters.

Ebastine is a long-acting, nonsedating, second-generation antihistaminic drug that prevents histamine action, mainly in immediate hypersensitivity. This project was aimed to formulate and characterize orodispersible tablets of ebastine, utilizing different proportions of three disintegrants, namely crospovidone, sodium starch glycolate, and coprocessed superdisintegrant. Initially, fifteen trial batches of ebastine orodispersible tablets were outlined using the central composite design of Minitab software. The tablets were formulated by the direct compression method. The compressed tablets were then evaluated for precompression and postcompression physicochemical parameters, such as angle of repose, Carr's index, Hausner's ratio, hardness, thickness, weight variation, drug content, friability, wetting time, disintegration time, dispersion time, and water absorption ratio. The in vitro dissolution test was conducted according to Indian Pharmacopeia 2018, with the help of the rotating paddle method using 0.5% w/v sodium lauryl sulfate buffer in 0.1 N HCl. For the optimized batch (8th batch), all the physicochemical parameters like angle of repose (33.77°), Carr's index (19.34%), Hausner's ratio (1.24), weight variation (202.5 mg), hardness (4.3 kg/cm2), friability (0.44%), thickness (3.16 mm), dissolution (95.78%), and drug content (101.67%) were within the acceptable limit as per Indian Pharmacopeia 2018. The wetting time, disintegration time, dispersion time, and water absorption ratio were reported to be 25.1 seconds, 16.0 seconds, 38.6 seconds, and 91.92%, respectively. Hence, the results suggested that orodispersible tablets of ebastine can be formulated. Furthermore, the mixing of crospovidone, sodium starch glycolate, and coprocessed super disintegrants can result in excellent desirable properties in the orodispersible tablet.

Development of Atorvastatin Calcium Biloaded Capsules for Oral Administration of Hypercholesterolemia.

The goal of this study was to develop atorvastatin (ATN) calcium biloaded, i.e., immediate release (IR) and sustained release (SR) capsules that would promote the quick onset of action and a better dissolution profile on both the IR and SR aspects. The IR granules were prepared by the wet granulation method, and an aqueous solubility study proved that the IR granules released the ATN within 25 min compared to the pure drug due to the addition of PEG and super disintegrants such as croscarmellose (CC) and crospovidone (CP). The sustained release nanoparticles (SR-NPs) were synthesized using a solvent evaporation technique and an optimal combination of hydrophilic and hydrophobic polymers. The addition of a hydrophobic polymer to a hydrophilic polymer delays drug release, resulting in a sustained and controlled release lasting up to 12 hours. The drug release of ATN from SR nanoparticles followed the Higuchi and Korsmeyer–Peppas models and had first-order kinetics (r2 = ???). Fourier transform infrared spectrophotometry, powder X-ray diffraction, and differential scanning calorimetric analysis were used to test the prepared biloaded capsules, and the results showed that there was no significant interaction between the polymers, excipients, and drug. The SEM and DLS analysis clearly demonstrated that drug particles in a continuous layer were enclosed by polymers at the nanoscale. To summarise, integrating both layers into a single capsule resulted in a superior release profile and patient compliance. Finally, prepared biloaded capsules were discovered to exhibit both an IR and an SR profile.